Home

Cristina Csimma

CIK 1501623 · last filed 2024-02-13

Cristina Csimma is a corporate insider who has filed 21 SEC Form 4 insider transactions across 6 companies since 2011. The most recent filing, for PALI, was dated Feb 13, 2024. Current disclosed insider exposure totals $1.2M across reported positions. 9 SEC filings were submitted jointly with COLUMBIA LABORATORIES INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.24M

Companies

6

Total Filings

21

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
14 CAMBRIDGE CENTER, BLDG 1
CAMBRIDGE, MA 02142
Related Filers
COLUMBIA LABORATORIES INC — 9 joint filings, latest 2018-08-15
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PALI Director 857 $2.01 $1.7K $0 4 2024-02-13
Aceragen, Inc. (IDRA) Delisted Director — $7.22 — $0 5 2022-06-27
PALISADE BIO, INC. (SNCA) Delisted Director — $9.96 — $0 2 2021-04-26
PALISADE BIO, INC. (CUR) Delisted Director — — — $0 3 2019-10-11
JUNIPER PHARMACEUTICALS INC (JNP) Delisted Director 0 — — $0 4 2018-08-15
CBRX Director 129,261 $9.57 $1.24M $0 3 2013-05-03

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-02-13 PALI Exer (M) +12,800 $0 EDGAR
2023-11-24 PALI Grant (A) — $0 EDGAR
2023-06-13 PALI Grant (A) — $0 EDGAR
2022-06-27 Aceragen, Inc. (IDRA) Delisted Grant (A) — $0 EDGAR
2022-02-10 PALI Grant (A) — $0 EDGAR
2021-06-10 Aceragen, Inc. (IDRA) Delisted Grant (A) — $0 EDGAR
2021-04-26 PALISADE BIO, INC. (SNCA) Delisted Grant (A) — $0 EDGAR
2020-05-19 Aceragen, Inc. (IDRA) Delisted Grant (A) — $0 EDGAR
2020-04-07 PALISADE BIO, INC. (SNCA) Delisted Grant (A) — $0 EDGAR
2019-10-11 PALISADE BIO, INC. (CUR) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.